Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Real-time Estimate Cboe BZX
Other stock markets
 01:53:35 2024-06-05 pm EDT 		5-day change 1st Jan Change
1.535 USD +6.60% Intraday chart for Marinus Pharmaceuticals, Inc. -0.32% -85.88%
May. 17 Sector Update: Health Care Stocks Mixed Late Afternoon MT
May. 17 Sector Update: Health Care MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors – MRNS
BU
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
AQ
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care
MT
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
MT
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program
CI
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
BU
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M
MT
Marinus Pharmaceuticals: Q1 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024
CI
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating
MT
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
BU
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating
MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2
MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.